文献速递脊柱关节炎其他结缔组织病

银屑病关节炎及合并症对银屑病患者乌司奴单抗结局的影响:一项回顾性观察性BADBIR队列研究

Impact of psoriatic arthritis and comorbidities on ustekinumab outcomes in psoriasis: a retrospective, observational BADBIR cohort study.
PubMed 文献 · RMD Open · 2023-01-01

基于英国皮肤科医师协会生物制剂与免疫调节剂注册库(BADBIR)的回顾性观察性队列研究,纳入9057例接受乌司奴单抗或传统系统性改善病情抗风湿药治疗的患者,比较单纯斑块状银屑病与合并银屑病关节炎(PsA)患者的基线差异及乌司奴单抗持续性和结局。结果显示PsA队列合并症负担更重,PsA(HR 1.98)、女性(男性HR 0.72)和抑郁(HR 1.21)与乌司奴单抗持续性缩短相关,抑郁和PsA对生活质量有负面影响。

要点

  • PsA队列的高血压、糖尿病、肥胖、抑郁合并症负担及无法工作比例高于单纯银屑病队列。
  • PsA(HR 1.98)、女性(男性HR 0.72)和抑郁(HR 1.21)与乌司奴单抗持续性缩短相关。
  • PsA与乌司奴单抗持续性的关联按PASI分层和既往生物制剂暴露而异,抑郁和PsA对生活质量有负面影响。

核心结论

  • 本研究发现合并症对治疗持续性有负面影响,强调在银屑病和PsA治疗中需以患者为中心、多学科筛查和管理合并症。
  • 作者认为应考虑心理支持以及对肥胖等可改变危险因素的生活方式管理。

研究设计与样本

  • 回顾性观察性队列研究,数据来自英国皮肤科医师协会生物制剂与免疫调节剂注册库(BADBIR)。
  • 纳入9057例接受乌司奴单抗或传统系统性改善病情抗风湿药治疗的患者。
  • 基线比较单纯斑块状银屑病队列与合并PsA队列;采用多变量Cox回归和Kaplan-Meier分析评估10年随访期间停药时间,并按交互协变量和PsA状态分层;采用广义线性混合模型评估基线特征对PASI和皮肤病生活质量指数随时间的影响。

主要发现

  • PsA队列的高血压、糖尿病、肥胖和抑郁合并症负担及无法工作比例高于单纯银屑病队列。
  • PsA(HR 1.98)、女性(男性HR 0.72)和抑郁(HR 1.21)与乌司奴单抗持续性缩短相关。
  • PsA与乌司奴单抗持续性的关联按PASI分层和既往生物制剂暴露而异。
  • 抑郁和PsA对生活质量有负面影响。

关键数值与推荐

  • PsA与乌司奴单抗持续性缩短相关(HR 1.98)。
  • 男性与乌司奴单抗持续性较长相关(HR 0.72)。
  • 抑郁与乌司奴单抗持续性缩短相关(HR 1.21)。

临床怎么用

  • 作者认为在银屑病和PsA治疗中需以患者为中心、多学科筛查和管理合并症。
  • 作者认为应考虑心理支持以及对肥胖等可改变危险因素的生活方式管理。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Psoriasis and psoriatic arthritis (PsA) are independently associated with comorbidities, including obesity and metabolic syndrome, which may impact treatment outcomes. This study aimed to assess baseline differences between patients with plaque psoriasis alone and those with concomitant PsA, and to investigate the impact of these characteristics on ustekinumab (UST) persistence and outcomes. METHODS: 9057 patients receiving UST or conventional systemic disease-modifying antirheumatic drugs were selected from the British Association of Dermatologists Biologic and Immunomodulators Register. The psoriasis and PsA cohorts were compared at baseline. Time to discontinuation during 10-year follow-up was assessed using multivariable Cox regression and Kaplan-Meier analyses, stratifying for interacting covariates and PsA status. Generalised linear mixed models assessed the impact of baseline characteristics on Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index over time. RESULTS: Greater comorbidity burden, including hypertension, diabetes, obesity and depression, and greater inability to work were observed in the PsA cohort than in the psoriasis cohort. PsA (HR 1.98), female sex (HR for male sex 0.72) and depression (HR 1.21) were associated with shorter UST persistence. PsA showed a differential association with UST persistence by PASI strata and prior biologic exposure. Quality of life was negatively impacted by depression and PsA. CONCLUSIONS: The negative impact of comorbidities on treatment persistence identified in this study emphasises the need for patient-centric, multidisciplinary care in screening for and managing comorbidities in psoriasis and PsA treatment. Psychological support and lifestyle management of modifiable risk factors, including obesity, should be considered.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Tillett W, Ogdie A, Passey A, et al. Impact of psoriatic arthritis and comorbidities on ustekinumab outcomes in psoriasis: a retrospective, observational BADBIR cohort study. RMD Open. 2023. PMID: 36650006. doi:10.1136/rmdopen-2022-002533

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。